Journal of Inflammation Research (Oct 2024)
NMDAR Down-Regulation: Dual – Hit Molecular Target For COPD – Depression Comorbidity
Abstract
Uriel Heresco-Levy,1,2 Jacob Haviv,1 Yehezkel G Caine1 1Herzog Medical Center, Jerusalem, Israel; 2Psychiatry Department, Hadassah Medical School, Hebrew University, Jerusalem, IsraelCorrespondence: Uriel Heresco-Levy, Herzog Medical Center, POBox 3900, Jerusalem, 91305, Israel, Tel +972-2-5316906, Fax +972-26075653, Email [email protected]: Chronic obstructive pulmonary disease (COPD) is a chronic lung disease characterized by sustained airflow limitation that represents one of the main causes of disability in modern society. Depression affects approximately 40% of COPD patients. Both COPD and depression are associated with chronic systemic inflammation and their comorbidity represents a critical unmet treatment need. N-methyl-D-aspartate glutamatergic receptors (NMDAR) are well characterized in the central nervous system (CNS) and widely expressed in lung tissue and inflammation-related cells. Accumulating evidence indicates that pathologic NMDAR up-regulation, leading to pro-inflammatory pathways activation and tissue damage, may play a crucial role in chronic lung injury as well as in depression. D-cycloserine, a bacteriostatic antibiotic used since the 1950’s in tuberculosis, acts at therapeutic dosages also as a NMDAR functional antagonist and has antidepressant and anti-inflammatory effects. We hypothesize that NMDAR down-regulation may represent a unified molecular target for the treatment of COPD – depression comorbidity and may simultaneously alleviate both respiratory and depression symptomatology. We postulate that D-cycloserine treatment may achieve these dual – hit objectives and envisage that our hypotheses may apply to additional inflammation disorders that are frequently accompanied by depression.Keywords: inflammation, depression, chronic obstructive pulmonary disease, N-methyl-D-aspartate receptor, D-cycloserine
